The retatrutide peptide represents a new frontier in metabolic science, not only for obesity but also for insulin resistance, fatty liver disease, cardiovascular risk, and type 2 diabetes complications
If constipation becomes an issue, increase fiber intake gradually and drink more water
Diagnosis is often made after 10 years of age
From Weeks 36 to 88, weight change was 5.5% with tirzepatide compared to +14.0% with placebo (difference 19.4%
Monitoring and Follow-Up During Retatrutide Treatment Trial participants undergo structured monitoring of weight, blood glucose, HbA1c, lipids, liver and renal function, blood pressure, and heart rate, typically every four weeks during dose escalation